Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling
今日の医薬品候補は、これまで以上に複雑化しています。But with development decisions on the line,…
Certara2025年2月12日
Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses
This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…
Danielle Pillsbury2025年1月21日
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region
The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…
Danielle Pillsbury2025年1月14日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
Danielle Pillsbury2025年1月9日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
Danielle Pillsbury2025年1月8日
From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations
SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…
Danielle Pillsbury2025年1月3日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation
This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…
Danielle Pillsbury2024年12月9日
PK/PD Data Analysis, Concepts and Applications eBook
複雑なプロセスを迅速化させましょう：PKサイエンティストのための基本書を用いて学んでいただけます。
Simona Colucci2024年11月25日
